Modified cupredoxin derived peptides

• US 9,434,770 B2
• Filed: 02/19/2009
• Issued: 09/06/2016
• Est. Priority Date: 10/07/2004
• Status: Active Grant

• Current Assignee: Craig W. Beattie, Tapas K. Das Gupta
• Original Assignee: Craig W. Beattie, Tapas K. Das Gupta
• Inventors: Das Gupta, Tapas K, Beattie, Craig W
• Primary Examiner(s): KINSEY WHITE, NICOLE ERIN
• Application Number:
  US12/389,120
• Publication Number:
  US 20090286719A1
• Time in Patent Office: 2,756 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 38/164 from bacteria
• CPC Class Codes: A61K 47/52 the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
• CPC Class Codes: A61K 47/6929 the form being a nanoparticle, e.g. an immuno-nanoparticle
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 33/06 Antimalarials
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/195 from bacteria
• CPC Class Codes: C07K 14/21 from Pseudomonadaceae (F)
• CPC Class Codes: C07K 2319/50 containing protease site
• CPC Class Codes: C07K 7/64 Cyclic peptides containing only normal peptide links
• CPC Class Codes: G01N 2333/16 HIV-1, HIV-2
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions related to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cells.

Claims

1. An isolated peptide consisting of SEQ ID NO:

13 that has one or more modified residue, wherein the modified residues comprises one or more residues that have been enzymatically cyclized, wherein the isolated peptide comprises a thioester bridge in a region from residue position 6 to residue position 16.

2. A pharmaceutical composition, comprising the isolated peptide of claim 1 and a pharmaceutically acceptable carrier.